In support of this hypothesis, recent work demonstrated that bortezomib, a proteasome inhibitor, induces the BH3-only protein NOXA, which can then downregulate, among other Bcl-2 protein family members, myeloid cell leukemia-1.17,26 However, VEBO may go beyond R/R ETP ALL cases. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.